Bladder cancer is the fourth most common cancer in the United States. Urothelial carcinoma that originates from the urinary bladder is the most common subtype. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations on the diagnosis and management of non–muscle-invasive and muscle-invasive urothelial carcinoma of the bladder. This version of the guidelines provides extensive reorganization and updates on the principles of chemotherapy management.

  • 1

    SiegelRNaishadhamDJemalA. Cancer statistics, 2012. CA Cancer J Clin2012;62:1029.

  • 2

    ChalasaniVChinJLIzawaJI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J2009;3:S193198.

    • Search Google Scholar
    • Export Citation
  • 3

    WascoMJDaignaultSZhangY. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology2007;70:6974.

    • Search Google Scholar
    • Export Citation
  • 4

    KamatAMDicksteinRJMessettiF. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial. J Urol2012;187:862867.

    • Search Google Scholar
    • Export Citation
  • 5

    GrossmanHBSolowayMMessingE. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA2006;295:299305.

  • 6

    American Urological Association. Guideline for the Management of Nonmuscle Invasive Bladder Cancer: (Stages TaT1 and Tis). 2007. Available at: http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines.cfm. Accessed November 27 2012.

    • Search Google Scholar
    • Export Citation
  • 7

    SylvesterRJvan der MeijdenAPOosterlinckW. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol2006;49:466–465; discussion 475–467.

    • Search Google Scholar
    • Export Citation
  • 8

    EdgeSByrdDComptonC eds. AJCC Cancer Staging Manual7th ed.New York: Springer; 2010.

  • 9

    MontironiRLopez-BeltranA. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol2005;13:143153.

  • 10

    BabjukMOosterlinckWSylvesterR. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol2011;59:9971008.

    • Search Google Scholar
    • Export Citation
  • 11

    HerrHW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol1999;162:7476.

  • 12

    SylvesterRJOosterlinckWvan der MeijdenAP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol2004;171:21862190quiz 2435.

    • Search Google Scholar
    • Export Citation
  • 13

    Berrum-SvennungIGranforsTJahnsonS. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol2008;179:101105; discussion 105–106.

    • Search Google Scholar
    • Export Citation
  • 14

    BohleALeyhHFreiC. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol2009;56:495503.

    • Search Google Scholar
    • Export Citation
  • 15

    GudjonssonSAdellLMerdasaF. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol2009;55:773780.

    • Search Google Scholar
    • Export Citation
  • 16

    HuncharekMMcGarryRKupelnickB. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res2001;21:765769.

    • Search Google Scholar
    • Export Citation
  • 17

    HuncharekMGeschwindJFWitherspoonB. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol2000;53:676680.

    • Search Google Scholar
    • Export Citation
  • 18

    GrimmMOSteinhoffCSimonX. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol2003;170:433437.

    • Search Google Scholar
    • Export Citation
  • 19

    BohleAJochamDBockPR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol2003;169:9095.

    • Search Google Scholar
    • Export Citation
  • 20

    HanRFPanJG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology2006;67:12161223.

    • Search Google Scholar
    • Export Citation
  • 21

    ShelleyMDKynastonHCourtJ. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int2001;88:209216.

    • Search Google Scholar
    • Export Citation
  • 22

    ShelleyMDWiltTJCourtJ. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int2004;93:485490.

    • Search Google Scholar
    • Export Citation
  • 23

    LokeshwarVBHabuchiTGrossmanHB. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology2005;66:3563.

    • Search Google Scholar
    • Export Citation
  • 24

    Ramirez-BackhausMDominguez-EscrigJColladoA. Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer. Curr Urol Rep2012;13:109114.

    • Search Google Scholar
    • Export Citation
  • 25

    DivrikRTYildirimUZorluFOzenH. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol2006;175:16411644.

    • Search Google Scholar
    • Export Citation
  • 26

    HerrHWSoganiPC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?J Urol2001;166:12961299.

    • Search Google Scholar
    • Export Citation
  • 27

    SteinbergGBahnsonRBrosmanS. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol2000;163:761767.

    • Search Google Scholar
    • Export Citation
  • 28

    RajGVHerrHSerioAM. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol2007;177:12831286; discussion 1286.

    • Search Google Scholar
    • Export Citation
  • 29

    BohleABockPR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology2004;63:682686; discussion 686–687.

    • Search Google Scholar
    • Export Citation
  • 30

    SylvesterRJvan derMALammDL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol2002;168:19641970.

    • Search Google Scholar
    • Export Citation
  • 31

    SylvesterRJvan der MeijdenAPWitjesJAKurthK. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol2005;174:8691; discussion 91–82.

    • Search Google Scholar
    • Export Citation
  • 32

    LammDLBlumensteinBACrissmanJD. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol2000;163:11241129.

    • Search Google Scholar
    • Export Citation
  • 33

    MalmstromPUSylvesterRJCrawfordDE. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol2009;56:247256.

    • Search Google Scholar
    • Export Citation
  • 34

    VermaSRajeshAPrasadSR. Urinary bladder cancer: role of MR imaging. Radiographics2012;32:371387.

  • 35

    LeissnerJHohenfellnerRThuroffJWWolfHK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int2000;85:817823.

    • Search Google Scholar
    • Export Citation
  • 36

    HerrHWBochnerBHDalbagniG. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol2002;167:12951298.

    • Search Google Scholar
    • Export Citation
  • 37

    HerrHWFaulknerJRGrossmanHB. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol2004;22:27812789.

    • Search Google Scholar
    • Export Citation
  • 38

    KonetyBRJoslynSAO'DonnellMA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol2003;169:946950.

    • Search Google Scholar
    • Export Citation
  • 39

    WrightJLLinDWPorterMP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer2008;112:24012408.

    • Search Google Scholar
    • Export Citation
  • 40

    GrossmanHBNataleRBTangenCM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med2003;349:859866.

    • Search Google Scholar
    • Export Citation
  • 41

    SherifAHolmbergLRintalaE. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol2004;45:297303.

    • Search Google Scholar
    • Export Citation
  • 42

    WinquistEKirchnerTSSegalR. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol2004;171:561569.

    • Search Google Scholar
    • Export Citation
  • 43

    Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol2005;48:202205; discussion 205–206.

    • Search Google Scholar
    • Export Citation
  • 44

    GriffithsGHallRSylvesterR. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol2011;29:21712177.

    • Search Google Scholar
    • Export Citation
  • 45

    HussainMHWoodDPBajorinDF. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol2009;27:56805684.

  • 46

    Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol2005;48:189199; discussion 199–201.

    • Search Google Scholar
    • Export Citation
  • 47

    LehmannJFranzaringLThuroffJ. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int2006;97:4247.

    • Search Google Scholar
    • Export Citation
  • 48

    StockleMWellekSMeyenburgW. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology1996;48:868875.

    • Search Google Scholar
    • Export Citation
  • 49

    SkinnerDGDanielsJRRussellCA. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol1991;145:459464; discussion 464–457.

    • Search Google Scholar
    • Export Citation
  • 50

    CognettiFRuggeriEMFeliciA. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol2012;23:695700.

    • Search Google Scholar
    • Export Citation
  • 51

    MillikanRDinneyCSwansonD. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol2001;19:40054013.

    • Search Google Scholar
    • Export Citation
  • 52

    ZaghloulMSAwwadHKAkoushHH. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys1992;23:511517.

    • Search Google Scholar
    • Export Citation
  • 53

    CozzariniCPellegriniDFalliniM. Reappraisal of the role of adjuvant radiotherapy in muscle-invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys1999;45(Suppl):221222.

    • Search Google Scholar
    • Export Citation
  • 54

    MakRHZietmanALHeneyNM. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int2008;102:13451353.

  • 55

    GakisGEfstathiouJLernerSP. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol2013;63:4557.

    • Search Google Scholar
    • Export Citation
  • 56

    FedeliUFedewaSAWardEM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol2011;185:7278.

    • Search Google Scholar
    • Export Citation
  • 57

    ShipleyWUKaufmanDSZehrE. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology2002;60:6267; discussion 67–68.

    • Search Google Scholar
    • Export Citation
  • 58

    ShipleyWUWinterKAKaufmanDS. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol1998;16:35763583.

    • Search Google Scholar
    • Export Citation
  • 59

    HerrHWBajorinDFScherHI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol1998;16:12981301.

    • Search Google Scholar
    • Export Citation
  • 60

    HoussetMMaulardCChretienY. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol1993;11:21502157.

    • Search Google Scholar
    • Export Citation
  • 61

    CoppinCMGospodarowiczMKJamesK. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol1996;14:29012907.

    • Search Google Scholar
    • Export Citation
  • 62

    JamesNDHussainSAHallE. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med2012;366:14771488.

  • 63

    HerrHW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol1987;138:11621163.

  • 64

    SweeneyPKurshEDResnickMI. Partial cystectomy. Urol Clin North Am1992;19:701711.

  • 65

    SternbergCNPansadoroVCalabroF. Can patient selection for bladder preservation be based on response to chemotherapy?Cancer2003;97:16441652.

    • Search Google Scholar
    • Export Citation
  • 66

    RodelCGrabenbauerGGKuhnR. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol2002;20:30613071.

    • Search Google Scholar
    • Export Citation
  • 67

    EfstathiouJASpiegelDYShipleyWU. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol2012;61:705711.

    • Search Google Scholar
    • Export Citation
  • 68

    ZapateroAMartin De VidalesCArellanoR. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology2012;80:10561062.

    • Search Google Scholar
    • Export Citation
  • 69

    KaufmanDSWinterKAShipleyWU. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist2000;5:471476.

    • Search Google Scholar
    • Export Citation
  • 70

    HaganMPWinterKAKaufmanDS. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys2003;57:665672.

    • Search Google Scholar
    • Export Citation
  • 71

    KaufmanDSWinterKAShipleyWU. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology2009;73:833837.

    • Search Google Scholar
    • Export Citation
  • 72

    EfstathiouJABaeKShipleyWU. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol2009;27:40554061.

    • Search Google Scholar
    • Export Citation
  • 73

    KaufmanDRaghavanDCarducciM. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol2000;18:19211927.

    • Search Google Scholar
    • Export Citation
  • 74

    von der MaaseHSengelovLRobertsJT. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol2005;23:46024608.

    • Search Google Scholar
    • Export Citation
  • 75

    SternbergCNde MulderPHSchornagelJH. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol2001;19:26382646.

    • Search Google Scholar
    • Export Citation
  • 76

    SternbergCNde MulderPSchornagelJH. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer2006;42:5054.

    • Search Google Scholar
    • Export Citation
  • 77

    von der MaaseHHansenSWRobertsJT. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol2000;18:30683077.

    • Search Google Scholar
    • Export Citation
  • 78

    De SantisMBellmuntJMeadG. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. J Clin Oncol2009;27:56345639.

    • Search Google Scholar
    • Export Citation
  • 79

    BurchPARichardsonRLChaSS. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol2000;164:15381542.

  • 80

    MeluchAAGrecoFABurrisHA3rd. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol2001;19:30183024.

    • Search Google Scholar
    • Export Citation
  • 81

    BellmuntJGuillemVPaz-AresL. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol2000;18:32473255.

    • Search Google Scholar
    • Export Citation
  • 82

    HussainMVaishampayanUDuW. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol2001;19:25272533.

    • Search Google Scholar
    • Export Citation
  • 83

    PectasidesDGlotsosJBountouroglouN. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol2002;13:243250.

    • Search Google Scholar
    • Export Citation
  • 84

    BellmuntJvon der MaaseHMeadGM. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol2012;30:11071113.

    • Search Google Scholar
    • Export Citation
  • 85

    LorussoVPolleraCFAntimiM. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer1998;34:12081212.

    • Search Google Scholar
    • Export Citation
  • 86

    McCaffreyJAHiltonSMazumdarM. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol1997;15:18531857.

    • Search Google Scholar
    • Export Citation
  • 87

    PapamichaelDGallagherCJOliverRT. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer1997;75:606607.

    • Search Google Scholar
    • Export Citation
  • 88

    VaughnDJBroomeCMHussainM. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol2002;20:937940.

    • Search Google Scholar
    • Export Citation
  • 89

    SweeneyCJRothBJKabbinavarFF. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol2006;24:34513457.

    • Search Google Scholar
    • Export Citation
  • 90

    GalskyMDIasonosAMironovS. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer2007;109:549555.

    • Search Google Scholar
    • Export Citation
  • 91

    GalskyMDMironovSIasonosA. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs2007;25:265270.

    • Search Google Scholar
    • Export Citation
  • 92

    WitteRSElsonPBonoB. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol1997;15:589593.

    • Search Google Scholar
    • Export Citation
  • 93

    HanKSJoungJYKimTS. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer2008;98:8690.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 481 481 59
PDF Downloads 77 77 9
EPUB Downloads 0 0 0